Innovative BBB Models HUREL's integration into Visikol and the recent launch of in vitro BBB assays and BBB models highlight a strong focus on blood-brain barrier research. This presents an opportunity to offer specialized testing services or collaborations to clients interested in neuropharmaceutical development and drug delivery studies.

Expanding Imaging Capabilities The launch of multiplex tissue imaging services and Imaging Mass Cytometry indicates advanced capabilities in tissue analysis. Sales efforts can target biotech and pharma companies seeking high-throughput, multi-marker tissue imaging solutions for drug discovery and biomarker validation.

Tissue Slice Expertise Development of precision cut tissue slice models for human and animal organs positions the company as a key provider of ex vivo models. Opportunities exist to partner with research institutions and biotech firms requiring organ-specific testing or preclinical validation tools.

Strong Financial Position With revenues between 10 to 25 million dollars and recent funding, HUREL and Visikol are positioned for growth and new project deployments. This financial stability can be leveraged to propose comprehensive research packages or customized service offerings to larger biotech clients.

Technological Leadership Utilization of diverse advanced tools like GraphPad Prism, HubSpot Analytics, and Microsoft platforms demonstrates technical proficiency. Sales strategies can emphasize the company's state-of-the-art approach to clients seeking cutting-edge research support and data analytics capabilities.